女性の健康治療薬の世界市場規模、シェア、成長分析、治療領域別、適応症別、流通チャネル別 - 産業予測、2024年～2031年

女性の健康治療薬の世界市場規模は、2022年に129億8,000万米ドルと評価され、2023年の137億米ドルから2031年には210億5,000万米ドルに成長し、予測期間（2024～2031年）のCAGRは5.52％で成長する見通しです。

世界の女性の健康治療薬市場には、ライフステージの異なる女性が直面する特有の健康ニーズや課題に対処することを目的とした、多様な医薬品や治療法が含まれています。女性の健康問題への注目がますます高まる中、この市場セグメントは、意識の高まり、医療技術の進歩、進化するヘルスケア政策などの要因によって、近年著しい拡大を見せています。リプロダクティブ・ヘルスや避妊から更年期管理、骨粗鬆症治療まで、この市場は女性特有のニーズに合わせた幅広い治療オプションを提供しています。最近では、乳がんや子宮頸がん、卵巣疾患、ループスや関節リウマチなどの自己免疫疾患など、女性が主に罹患する疾患を対象とした研究開発が重視されています。さらに、医学的介入だけでなく、ライフスタイルの改善、メンタルヘルス支援、教育や予防医療へのアクセスなどを含む、女性の健康に対する全人的アプローチの重要性が認識されつつあります。大きな進展にもかかわらず、ヘルスケア・サービスへのアクセスにおける格差、臨床試験における女性の割合の低さ、特定の健康問題を取り巻く偏見など、女性の健康に関する治療薬市場には課題が残っています。これらの課題に対処するためには、質の高いケアへの公平なアクセスと女性の健康ニーズに対する包括的な支援を世界中で確保するために、医療提供者、政策立案者、製薬会社、アドボカシー団体が一致団結して取り組む必要があります。医学研究、テクノロジー、ヘルスケア提供の継続的な進歩により、イノベーションが促進され、世界中の女性の転帰が改善されることが期待されます。しかし、有意義な進歩を達成するためには、研究、教育、アドボカシー活動への継続的な協力と投資が必要であり、女性が自分の健康と幸福を管理できるようにする必要があります。女性の健康を公衆衛生の課題とヘルスケアシステムの中心的な要素として優先させることで、私たちは、すべての女性が健康で充実した生活を送るために必要なケアとサポートを利用できる未来に向けて取り組むことができます。

目次

エグゼクティブサマリー

• 市場概要
• 運命の輪

調査手法

• 情報調達
• セカンダリおよびプライマリデータソース
• 市場規模の推定
• 市場の前提条件と制限

親市場の分析

• 市場概要
• 市場規模
• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題

主な市場の考察

• 技術分析
• 価格分析
• サプライチェーン分析
• バリューチェーン分析
• 市場のエコシステム
• IP分析
• 貿易分析
• スタートアップ分析
• 原材料の分析
• イノベーションマトリクス
• パイプライン製品の分析
• マクロ経済指標
• 主な投資の分析
• 主な成功要因
• 競合の程度

市場力学と見通し

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• 規制情勢
• ポーターの分析
• 将来の混乱についての特別な考察

女性の健康治療薬の世界市場：治療領域別

• 市場概要
• ホルモン療法
• 避妊薬
• リプロダクティブヘルス薬
• その他

女性の健康治療薬の世界市場：適応症別

• 市場概要
• 閉経
• 避妊
• ホルモン関連のがん
• 生殖障害
• その他

女性の健康治療薬の世界市場：流通チャネル別

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局
• その他

女性の健康治療薬の世界市場規模：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • その他の欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他のアジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他のラテンアメリカ
• 中東・アフリカ（MEA）
  • GCC諸国
  • 南アフリカ
  • その他の中東・アフリカ

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2021年）
• 主な市場企業が採用した戦略
• 主要成功戦略
• 市場における最近の活動
• 主要企業の市場シェア（2021年）

主要企業プロファイル

• Pfizer Inc.（United States）
• Bayer AG（Germany）
• Novartis AG（Switzerland）
• GlaxoSmithKline plc（United Kingdom）
• Merck & Co., Inc.（United States）
• AbbVie Inc.（United States）
• Eli Lilly and Company（United States）
• AstraZeneca plc（United Kingdom）
• Johnson & Johnson（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Eisai Co., Ltd.（Japan）
• Otsuka Pharmaceutical Co., Ltd.（Japan）
• Shionogi & Co., Ltd.（Japan）
• Mitsubishi Tanabe Pharma Corporation（Japan）
• Daiichi Sankyo Company, Limited（Japan）
• Astellas Pharma Inc.（Japan）
• Sanofi（France）
• Bristol Myers Squibb Company（United States）
• Allergan plc（Ireland）

Global Women's Health Therapeutics Market size was valued at USD 12.98 billion in 2022 and is poised to grow from USD 13.70 billion in 2023 to USD 21.05 billion by 2031, growing at a CAGR of 5.52% in the forecast period (2024-2031).

The global women's health therapeutics market encompasses a diverse array of pharmaceuticals and treatments aimed at addressing the unique health needs and challenges faced by women across different stages of life. With an ever-growing focus on women's health issues, this market segment has seen significant expansion in recent years, driven by factors such as increasing awareness, advancements in medical technology, and evolving healthcare policies. From reproductive health and contraception to menopause management and osteoporosis treatment, the market offers a wide range of therapeutic options tailored to meet the specific needs of women. In recent times, there has been a heightened emphasis on research and development efforts targeting conditions that predominantly affect women, such as breast and cervical cancers, ovarian disorders, and autoimmune diseases like lupus and rheumatoid arthritis, among others. Additionally, there is a growing recognition of the importance of holistic approaches to women's health, which encompass not only medical interventions but also lifestyle modifications, mental health support, and access to education and preventive care. Despite significant progress, challenges persist in the women's health therapeutics market, including disparities in access to healthcare services, underrepresentation of women in clinical trials, and stigma surrounding certain health issues. Addressing these challenges requires a concerted effort from healthcare providers, policymakers, pharmaceutical companies, and advocacy groups to ensure equitable access to quality care and comprehensive support for women's health needs worldwide. Looking ahead, the future of the global women's health therapeutics market appears promising, with continued advancements in medical research, technology, and healthcare delivery expected to drive innovation and improve outcomes for women across the globe. However, achieving meaningful progress will require ongoing collaboration and investment in research, education, and advocacy efforts to empower women to take charge of their health and well-being. By prioritizing women's health as a central component of public health agendas and healthcare systems, we can work towards a future where all women have access to the care and support, they need to live healthy, fulfilling lives.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Women's Health Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Women's Health Therapeutics Market Segmental Analysis

The global women's health therapeutics market is segmented into four major segments i.e. by therapeutic area, indication, distribution channel, and region. Based on type, it is divided into hormone therapies, contraceptives, reproductive health drugs, and others. Based on Indication, it is bifurcated as menopause, contraception, hormone-related cancers, reproductive disorders, and others. Based on distribution channel it is segregated into, hospital pharmacies, retail pharmacies, online pharmacies, and others. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

Drivers of the Global Women's Health Therapeutics Market

One significant driver propelling the growth of the global women's health therapeutics market is increasing awareness and advocacy for women's health issues. Over the past decade, there has been a notable surge in public awareness campaigns, educational initiatives, and policy efforts aimed at addressing women's health concerns. This heightened awareness has led to improved diagnosis rates, greater access to healthcare services, and increased demand for innovative therapies tailored to women's specific needs. Additionally, advancements in medical research and technology have expanded the scope of treatment options available, driving market growth further.

Restraints in the Global Women's Health Therapeutics Market

However, alongside these drivers, several restraints challenge the market's expansion. One notable restraint is the lingering stigma and cultural barriers surrounding women's health issues in many parts of the world. Societal taboos, misconceptions, and cultural norms can hinder women from seeking timely medical care or discussing their health concerns openly. Addressing these barriers requires comprehensive education and awareness campaigns, as well as culturally sensitive approaches to healthcare delivery.

Market Trends of the Global Women's Health Therapeutics Market

Moreover, a significant trend shaping the women's health therapeutics market is the growing emphasis on personalized medicine and precision healthcare. As our understanding of genetic predispositions and individual variations in drug responses improves, there is a shift towards tailored treatment approaches that consider each patient's unique biology, lifestyle, and health history. This trend is driving investments in genomic medicine, biomarker research, and targeted therapies, enabling more precise and effective interventions for women's health conditions. Additionally, the integration of digital health technologies, such as mobile apps and wearable devices, is enhancing patient engagement, remote monitoring, and data-driven healthcare decision-making, thereby transforming the delivery of women's health services.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Women's Health Therapeutics Market by Therapeutic Area

• Market Overview
• Hormone Therapies
• Contraceptives
• Reproductive Health Drugs
• and others

Global Women's Health Therapeutics Market by Indication

• Market Overview
• Menopause
• Contraception
• Hormone-related Cancers
• Reproductive Disorders
• and others

Global Women's Health Therapeutics Market by Distribution channel

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• and Others

Global Women's Health Therapeutics Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shionogi & Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments